Chumpitazi BP, Kearns GL, Shulman RJ
This is the most common symptom in individuals who are on semaglutide
Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in vivo models of neurodegenerative diseases through modulating a variety of pathogenic mechanisms, including neuroinflammation, autophagy, mitochondrial dysfunction, and the abnormal phosphorylation of pathognomonic proteins
If the medicine doesnt work for me or my insurance doesnt cover it, what other options do I have
No medical oversight, dosing guidance, or safety monitoring
Decisions about starting, stopping or switching treatment should be made by the doctor who prescribed it, because they need to weigh the full benefits and risks for your individual situation